Rare & Genetic Diseases
| 2 min read
New research published in journal PLoS shows silencing of alpha-synuclein in the substantia nigra of non-human
primates with an RNAi therapeutic
| 3 min read
Pharma acquires pharmaceutical company to boost its specialty care business
| 1 min read
Acquisition set to enhance Recipharm’s presence in Southern Europe
| 4 min read
Strategy could benefit gene discovery for thousands of rare diseases
| 3 min read
Scientists at the Genome Institute of Singapore (GIS) have found that a genetic
molecule, Tbx3, which is important to the early developmental processes in mammals, can improve the quality of stem cells that have been reprogrammed from
differentiated cells
| 4 min read
Company pushing forward with established and new HybSelect technology to capture NGS market
| 3 min read
Ipsen and Inspiration Biopharmaceuticals to create
hemophilia franchise
| 3 min read
Seaside Therapeutics, Vanderbilt collaborate on novel
therapeutics to treat Fragile X, autism, other brain disorders
| 2 min read
Seeking to advance its position as a developer of blood cancer therapies, Celgene Corp. announced Dec. 9 that it has reached an agreement to acquire Gloucester Pharmaceuticals, a privately held biotech based in Cambridge, Mass., for $340 million in cash plus $300 million in future U.S. and international regulatory milestone payments.
| 3 min read
mondoBIOTECH and Bachem sign long-term deal aimed at fighting rare diseases
